Induction of Apoptosis and Cell-Growth Inhibition by Protein 4-33
OHSU # 0490
Insulin-like growth factor binding protein 3 (IGFBP-3), a member of the IGFBP superfamily and the most abundant binding protein in human serum, is recognized to play an important role in growth regulation of cancer cells. There is strong evidence showing the inhibitory action of IGFBP-3 on the growth of various tumors, including breast, cervical, lung, non-small cell lung, colon and prostate. This invention covers the identification and characterization of a novel protein, Protein 4.33, that interacts specifically with IGFBP-3 and such interaction is an important mechanism in the insulin growth factor-independent, growth inhibitory and apoptotic actions of IGFBP-3.
Protein 4.33 is involved in the inhibition of DNA synthesis and cellular proliferation, and in the induction of apoptosis in cancer cells. The Protein 4.33:IGFBP-3 system of the present invention can be used, inter alia, in screening and diagnostic assays, and for therapeutic methods for cancer treatment and tumor suppression. There is a need in the art to determine the nature and mechanism of how IGFBP-3 modulates cancer cell growth and apoptosis in an insulin growth factor-independent manner. There is a further need in the art to understand how such a mechanism, once determined, could be used therapeutically, or to fine therapeutic agents, or to provide useful diagnostic and prognostic assays for various cancers.
Technology #0490 provides drug candidate screening assays, and diagnostic and therapeutic methods for the treatment of cancer and tumor suppression, utilizing the novel IGFBP-3 interacting protein called Protein 4.33 as the intervention target. The present technology also provides a Protein 4.33 cDNA sequence, a Protein 4.33 polypeptide and fragments thereof, and an anti-Protein 4.33 antibody.
Issued US Patent 7,585,497 covers the methods of treating cancer
Pending patent applications in the US, Canada and Europe covering the DNA sequences, the protein, methods of treating cancer, screening methods, therapeutic antibody, and pharmaceutical compositions.
Dr. Youngman Oh received his PhD from Stanford University in Cancer Biology. He held numerous positions at Oregon Health & Science University in the Department of Pediatrics, Cell and Development Biology Department, and the Cancer Institute. In 2003, Dr. Oh became a Professor in the Department of Pathology and the Department of Biochemisty at the Medical College of Virginia Campus, Virginia Commonwealth University. He is also the Director of the Oncogeomics Program at VCU.
According to the American Cancer Society, in the United States it is estimated that there will be 192,280 new cases of prostate cancer and 27,360 deaths from the disease in 2009. Prostate cancer is the most common type of cancer found in American men, other than skin cancer, and the second leading cause of cancer death in men. One in every six men will get prostate cancer during his lifetime, and one man in 35 will die of this disease.
Breast cancer incidence in women in the U.S. is 1 in 8. For 2009 in the U.S., it is estimated that there will be 192,370 new cases in women and 1,910 in men, along with 40,170 deaths of women and 440 deaths of men. Among cancers for women in the U.S., breast cancer is the second leading killer.
The two main types of lung cancer are small cell lung cancer and non-small cell lung cancer. It is estimated that there will be 219,440 new cases of lung cancer (combined) in the U.S. in 2009 along with 159,390 deaths from the disease. Lung cancer is the leading cause of cancer death.
Colorectal cancer is the third most commonly diagnosed cancer. New cases of colon and rectal cancers are to reach 146,970 for 2009 in the U.S. with 49,920 deaths from them combined.
Cervical cancer is almost always caused by human papillomavirus infection. In the U.S. for 2009 it is estimated that there will be 11,270 new cases of cervical cancer and 4,070 deaths from the disease.
Cancer Res. 2004 Mar 15;64(6):2229-37.
OHSU #490 is available for exclusive licensing.
|Published||European Patent Convention||1290162|
Other Patents Filed
For more information, contact:
Technology Development Manager